Abstract PD3-6: A phase 1 open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide (previously MDV3100) alone or in combination with an aromatase inhibitor in women with advanced breast cancer

@inproceedings{Traina2013AbstractPA,
  title={Abstract PD3-6: A phase 1 open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide (previously MDV3100) alone or in combination with an aromatase inhibitor in women with advanced breast cancer},
  author={Ta Traina and Denise A Yardley and Manish R Patel and Lee S Schwartzberg and Anthony D. Elias and Ayca Gucalp and Amy C. Peterson and Alison L. Hannah and Jacqueline A. Gibbons and Zakaria Khondker and Ca Hudis and Patricia Lorusso},
  year={2013}
}
Background: Enzalutamide (ENZA) is a potent novel oral inhibitor of androgen receptor (AR) signaling. AR expression is observed in ∼70% of breast cancers (BC) and across the 3 major histologic subtypes (ER+, HER2+ and triple negative) [Collins LC et al. Mod Pathol 2011; 24:924-31]. Based on findings in preclinical models of AR+ BC, the potential therapeutic effect of ENZA in AR+ BC is being evaluated. This is the first trial of ENZA in women with advanced BC (aBC). Methods : This Phase 1 study… CONTINUE READING